This was a non-interventional retrospective cohort study of de novo heart failure with reduced ejection fraction (HFrEF) patients (aged ≥18 years) commencing first-line treatment on either sacubitril/valsartan or commencing or continuing angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blocker (ARB) therapy for HF in the United States (US) using the secondary source of data, Optum Electronic Health Records (EHR).
Study Type
OBSERVATIONAL
Enrollment
9,870
Novartis
East Hanover, New Jersey, United States
Total number of all-cause hospitalizations
Time frame: Up to approximately 5 years
Time to first all-cause hospitalization
Time frame: Up to approximately 5 years
Number and proportion of HF-specific inpatient hospitalizations
Time frame: Up to approximately 5 years
Number and proportion of HF-related inpatient hospitalizations
Time frame: Up to approximately 5 years
Number and proportion of cardiovascular (CV)-specific inpatient hospitalizations
Time frame: Up to approximately 5 years
Numbers and proportions of first and recurrent (1st, 2nd, 3rd, 4th and 5th) all-cause inpatient hospitalizations
Time frame: Up to approximately 5 years
Numbers and proportions of first and recurrent (1st, 2nd, 3rd, 4th and 5th) HF-specific inpatient hospitalizations.
Time frame: Up to approximately 5 years
Number and proportion of patients with ≥1 implantable cardioverter defibrillator (ICD) insertion during a hospitalization or during an emergency room (ER) visit for both the sacubitril/valsartan and ACEi/ARB cohorts
Time frame: Up to approximately 5 years
Number and proportion of non-HF inpatient hospitalizations
Time frame: Up to approximately 5 years
Number and proportion of non-CV inpatient hospitalizations
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Up to approximately 5 years
Dosages and dose changes of sacubitril/valsartan administered
Time frame: Up to approximately 5 years